Abbott Laboratories vs Merck & Company, Inc. — Stock Comparison
Abbott Laboratories (ABT) and Merck & Company, Inc. (MRK) are both listed on US exchanges. This page compares their Q·Score ratings, key fundamentals (P/E, margins, growth), and Wall Street analyst consensus side by side. Data sourced from Yahoo Finance and updated on each page load.
Abbott Laboratories narrowly edges Merck & Company, Inc. on Q·Score (7.1 vs 7 out of 10), led by Valuation (8.6 vs 6.7) and Sentiment (7.6 vs 7.1). Merck & Company, Inc. scores higher on Growth, reflecting stronger revenue and earnings momentum. Analyst consensus targets imply greater upside for ABT (+31.4%) than for MRK (+12.9%).
Price Performance
Normalised to 100 at period start — shows relative performance.
Q·Score Breakdown
Consensus analyst target of $116.54 is 31% above current price.
⚠ earnings contracting 20% year-over-year.
High-quality business with 19% return on equity and 14% profit margins.
Analyst Consensus
Fundamentals
Frequently Asked Questions
ABT vs MRK: which stock scores better overall?
Based on Q·Score, Abbott Laboratories (ABT) scores 7.1/10 versus Merck & Company, Inc. (MRK) at 7/10. The Q·Score measures five dimensions: Quality, Health, Growth, Valuation, and Sentiment. For informational purposes only — not financial advice.
Which has better revenue growth: ABT or MRK?
Merck & Company, Inc. (MRK) scores higher on Growth (6.2/10 vs 4.7/10). Abbott Laboratories reports revenue growth (7.8% YoY) while Merck & Company, Inc. reports (4.9% YoY). Growth scores reflect revenue and earnings momentum relative to sector peers.
Is ABT or MRK more attractively valued?
Abbott Laboratories (ABT) scores higher on Valuation (8.6/10 vs 6.7/10). ABT trades at 14.6× P/E versus MRK at 12.0×. Valuation is assessed using P/E ratio, analyst price targets, and 52-week range positioning relative to sector peers.
What do analysts say about ABT vs MRK?
There are 24 analysts covering ABT with a consensus price target of $116.54, and 27 analysts covering MRK with a consensus target of $129.74. Analyst consensus ratings are aggregated from Wall Street research and do not constitute investment advice.
Which is more profitable: ABT or MRK?
Abbott Laboratories (ABT) scores higher on Quality (7.7/10 vs 7.7/10). Net profit margin: ABT at 13.9%, MRK at 13.6%. Quality scores reflect profit margins, return on equity, and free cash flow generation.
Which has stronger financial health: ABT or MRK?
Abbott Laboratories (ABT) scores higher on Financial Health (7/10 vs 7/10). Market beta: ABT at 0.62, MRK at 0.22. Health scores consider beta, debt-to-equity, and current ratio. All investments carry risk — this is not investment advice.
What are the market caps of ABT and MRK?
Abbott Laboratories (ABT) has a market capitalisation of $154.4B, while Merck & Company, Inc. (MRK) has a market cap of $283.8B. Market cap data is sourced from Yahoo Finance and reflects the most recent available figures.
Do ABT or MRK pay dividends?
ABT pays a dividend yield of 2.84%, while MRK pays a dividend yield of 2.96%. Dividend yields fluctuate with share price and company payout decisions.
Related Comparisons
Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →